Author

S. Hanaoka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

S. Saijou· 2 shared Y. Matsumura· 2 shared H. Takashima· 1 shared M. Hara· 1 shared M. Yasunaga· 1 shared T. Anzai· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

S. Saijou

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification of CD73 as the antigen of an antigen-unknown monoclonal antibody established by exosome immunization, and its antibody-drug conjugate exerts an antitumor effect on glioblastoma cell lines

T. Anzai, S. Saijou, H. Takashima, M. Hara, S. Hanaoka, Y. Matsumura, M. Yasunaga

This paper identifies CD73 as the antigen of a monoclonal antibody generated by exosome immunization and shows its antibody-drug conjugate has antitumor effects on glioblastoma cell lines.

bioRxiv · Sep 30, 2021 · PreprintBiophysics

A novel and potent thrombolytic fusion protein consisting of anti-insoluble fibrin antibody and mutated urokinase

S. Hanaoka, S. Saijou, Y. Matsumura

This paper develops a thrombolytic fusion protein, AMU1114, that selectively targets insoluble fibrin, reducing systemic side effects compared to tPA and UK.

bioRxiv · Sep 6, 2020Pharmacology & Toxicology